{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T08:35:41Z","timestamp":1770453341415,"version":"3.49.0"},"reference-count":87,"publisher":"Jaypee Brothers Medical Publishing","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.59556\/japi.72.0543","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T02:52:27Z","timestamp":1751943147000},"page":"77-88","source":"Crossref","is-referenced-by-count":0,"title":["Consensus Statement from India on the Renal Benefits of ARNi, SGLT-2i, and Bisoprolol in Chronic Kidney Disease"],"prefix":"10.59556","volume":"72","author":[{"given":"H K","family":"Chopra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinesh","family":"Khullar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiny","family":"Nair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G S","family":"Wander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C K","family":"Ponde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saumitra","family":"Ray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Navin C","family":"Nanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi R","family":"Kasliwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DS","family":"Rana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashok","family":"Kirpalani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JPS","family":"Sawhney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Praveen","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yatin","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viveka","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Tewari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A K","family":"Pancholia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay","family":"Kher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Praful","family":"Kerkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P K","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramesh","family":"Hotchandani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nagendra","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishal","family":"Rastogi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Jabir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Shanmugasundaram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mangesh","family":"Tiwaskar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittul","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SS","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S N","family":"Routray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A K","family":"Omar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onkar C","family":"Swami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aparna","family":"Jaswal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shamsad","family":"Alam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajeev","family":"Passey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajeeve","family":"Rajput","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditya","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Prabhakar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subhash","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Poonam","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivudh Pratap","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manish","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyank","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohan","family":"Bhargava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I B","family":"Vijayalakshmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiron","family":"Varghaese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dharmender","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anupam","family":"Goel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Namrata","family":"Gaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit","family":"Tandon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asha","family":"Moorthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheeba","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V K","family":"Katyal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"RR","family":"Mantri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahul","family":"Mehrotra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilip","family":"Bhalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinod","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarita","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manish","family":"Jagia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harmeet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surabhi","family":"Awasthi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ameet","family":"Sattur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rekha","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anand","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajeev","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shalini","family":"Jaggi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blessy","family":"Sehgal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alok","family":"Sehgal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naresh","family":"Goel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ripen","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samir","family":"Kubba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhinav","family":"Chhabra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saurabh","family":"Bagga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N R","family":"Shastry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2914","reference":[{"issue":"(1):","key":"key20250708065221_B1","doi-asserted-by":"crossref","first-page":"60\u2013","DOI":"10.1093\/ckj\/sfab149","article-title":"The Indian Chronic Kidney Disease (ICKD) study: baseline characteristics.","volume":"15","author":"Kumar","year":"2022;","journal-title":"Clin Kidney J"},{"issue":"(2):","key":"key20250708065221_B2","doi-asserted-by":"crossref","first-page":"79\u2013","DOI":"10.4103\/ijn.ijn_125_23","article-title":"Renal revolution: anticipating the next 25 years of India\u2019s kidney care.","volume":"33","author":"Jha","year":"2023;","journal-title":"Indian J Nephrol"},{"issue":"(5):","key":"key20250708065221_B3","doi-asserted-by":"crossref","first-page":"684.","DOI":"10.34067\/KID.0000000000000124","article-title":"Journey of a Patient with CKD in India.","volume":"4","author":"Raghavan","year":"2023;","journal-title":"Kidney360"},{"issue":"(1)","key":"key20250708065221_B4","article-title":"Survival and analysis of predictors of mortality in patients undergoing hemodialysis in a rural hospital in Puducherry, India: a retrospective cohort study.","volume":"16","author":"Ravi Kumar","year":"2023;","journal-title":"Open Urol Nephrol J"},{"issue":"(1):","key":"key20250708065221_B5","doi-asserted-by":"crossref","first-page":"e89\u2013","DOI":"10.1016\/S2214-109X(16)30308-4","article-title":"Renal failure deaths and their risk factors in India 2001-13: nationally representative estimates from the Million Death Study.","volume":"5","author":"Dare","year":"2017;","journal-title":"Lancet Glob Health"},{"issue":"(18):","key":"key20250708065221_B6","doi-asserted-by":"crossref","first-page":"6105.","DOI":"10.3390\/jcm12186105","article-title":"Heart failure in patients with chronic kidney disease.","volume":"12","author":"Xanthopoulos","year":"2023;","journal-title":"J Clin Med"},{"issue":"(5):","key":"key20250708065221_B7","doi-asserted-by":"crossref","first-page":"294\u2013","DOI":"10.1038\/s41581-022-00535-6","article-title":"Kidney and heart failure outcomes associated with SGLT2 inhibitor use.","volume":"18","author":"van der Aart-van der Beek","year":"2022;","journal-title":"Nat Rev Nephrol"},{"issue":"(4):","key":"key20250708065221_B8","doi-asserted-by":"crossref","first-page":"584\u2013","DOI":"10.1002\/ejhf.1697","article-title":"Evaluation of kidney function throughout the heart failure trajectory - a position statement from the Heart Failure Association of the European Society of Cardiology.","volume":"22","author":"Mullens","year":"2020;","journal-title":"Eur J Heart Fail"},{"issue":"(4):","key":"key20250708065221_B9","doi-asserted-by":"crossref","first-page":"555\u2013","DOI":"10.23876\/j.krcp.21.900","article-title":"Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease.","volume":"40","author":"Cho","year":"2021;","journal-title":"Kidney Res Clin Pract"},{"issue":"(4):","key":"key20250708065221_B10","doi-asserted-by":"crossref","first-page":"603\u2013","DOI":"10.1002\/ejhf.2471","article-title":"Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology.","volume":"24","author":"Mullens","year":"2022;","journal-title":"Eur J Heart Fail"},{"issue":"(9):","key":"key20250708065221_B11","doi-asserted-by":"crossref","first-page":"693\u2013","DOI":"10.1161\/CIRCULATIONAHA.121.052792","article-title":"Evidence-based medical therapy in patients with heart failure with reduced ejection fraction and chronic kidney disease.","volume":"145","author":"Beldhuis","year":"2022;","journal-title":"Circulation"},{"issue":"(3)","key":"key20250708065221_B12","article-title":"Chronic kidney disease as a comorbidity in heart failure.","volume":"24","author":"Szlagor","year":"2023;","journal-title":"Int J Mol Sci"},{"issue":"(1):","key":"key20250708065221_B13","first-page":"P16\u2013","article-title":"Updates on new therapies for patients with chronic kidney disease.","volume":"9","author":"Tarun","year":"2023;","journal-title":"Kidney Int Rep"},{"issue":"(4):","key":"key20250708065221_B14","first-page":"11\u2013","article-title":"Angiotensin receptor-neprilysin inhibitor therapy and cardiac remodeling in heart failure: consensus statement from India.","volume":"71","author":"Chopra","year":"2023;","journal-title":"J Assoc Physicians India"},{"issue":"(6):","key":"key20250708065221_B15","doi-asserted-by":"crossref","first-page":"3792\u2013","DOI":"10.1002\/ehf2.12965","article-title":"Renal function dynamics following co-administration of sacubitril\/valsartan and empagliflozin in patients with heart failure and type 2 diabetes.","volume":"7","author":"de la Espriella","year":"2020;","journal-title":"ESC Heart Fail"},{"key":"key20250708065221_B16","doi-asserted-by":"crossref","first-page":"794707.","DOI":"10.3389\/fcvm.2022.794707","article-title":"Angiotensin receptor-neprilysin inhibitors in patients with heart failure with reduced ejection fraction and advanced chronic kidney disease: a retrospective multi-institutional study.","volume":"9:","author":"Hsiao","year":"2022;","journal-title":"Front Cardiovasc Med"},{"key":"key20250708065221_B17","doi-asserted-by":"crossref","first-page":"877237.","DOI":"10.3389\/fmed.2022.877237","article-title":"Application of angiotensin receptor-neprilysin inhibitor in chronic kidney disease patients: Chinese expert consensus.","volume":"9:","author":"Gan","year":"2022;","journal-title":"Front Med (Lausanne)"},{"issue":"(20):","key":"key20250708065221_B18","doi-asserted-by":"crossref","first-page":"1569\u2013","DOI":"10.1136\/heartjnl-2017-311295","article-title":"Sacubitril\/valsartan: beyond natriuretic peptides.","volume":"103","author":"Singh","year":"2017;","journal-title":"Heart"},{"issue":"(6):","key":"key20250708065221_B19","doi-asserted-by":"crossref","first-page":"3487\u2013","DOI":"10.1002\/ehf2.13002","article-title":"Effect of sacubitril\/valsartan on renal function: a systematic review and meta-analysis of randomized controlled trials.","volume":"7","author":"Spannella","year":"2020;","journal-title":"ESC Heart Fail"},{"key":"key20250708065221_B20","doi-asserted-by":"crossref","first-page":"754499.","DOI":"10.3389\/fcvm.2021.754499","article-title":"Sacubitril-valsartan, clinical benefits and related mechanisms of action in heart failure with reduced ejection fraction. A review.","volume":"8:","author":"Pascual-Figal","year":"2021;","journal-title":"Front Cardiovasc Med"},{"issue":"(1):","key":"key20250708065221_B21","doi-asserted-by":"crossref","first-page":"26\u2013","DOI":"10.1016\/j.kint.2017.12.027","article-title":"Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.","volume":"94","author":"Heerspink","year":"2018;","journal-title":"Kidney Int"},{"issue":"(1):","key":"key20250708065221_B22","doi-asserted-by":"crossref","first-page":"23\u2013","DOI":"10.15420\/ecr.2018.34.2","article-title":"Sodium-glucose cotransporter 2 inhibitors in heart failure: potential mechanisms of action, adverse effects and future developments.","volume":"14","author":"Tamargo","year":"2019;","journal-title":"Eur Cardiol"},{"issue":"(10):","key":"key20250708065221_B23","doi-asserted-by":"crossref","first-page":"2795\u2013","DOI":"10.1111\/dom.15181","article-title":"Management of the \u2019wicked\u2019 combination of heart failure and chronic kidney disease in the patient with diabetes.","volume":"25","author":"Bell","year":"2023;","journal-title":"Diabetes Obes Metab"},{"issue":"(11):","key":"key20250708065221_B24","doi-asserted-by":"crossref","first-page":"e0165703.","DOI":"10.1371\/journal.pone.0165703","article-title":"Effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on renal renin-angiotensin system in an animal model of type 2 diabetes.","volume":"11","author":"Shin","year":"2016;","journal-title":"PLoS One"},{"issue":"(9):","key":"key20250708065221_B25","doi-asserted-by":"crossref","first-page":"873\u2013","DOI":"10.1016\/S0300-8932(03)76975-9","article-title":"[Use of bisoprolol in heart failure. The BISOCOR observational study].","volume":"56","author":"Gonz\u00e1lez-Juanatey","year":"2003;","journal-title":"Rev Esp Cardiol"},{"issue":"(5):","key":"key20250708065221_B26","doi-asserted-by":"crossref","first-page":"558\u2013","DOI":"10.1161\/01.CIR.101.5.558","article-title":"Beta-adrenergic receptor blockade in chronic heart failure.","volume":"101","author":"Bristow","year":"2000;","journal-title":"Circulation"},{"issue":"(8):","key":"key20250708065221_B27","doi-asserted-by":"crossref","first-page":"334\u2013","DOI":"10.1002\/pdi.1298","article-title":"Bisoprolol.","volume":"25","author":"Smith","year":"2008;","journal-title":"Pract Diabet Int"},{"issue":"(15):","key":"key20250708065221_B28","doi-asserted-by":"crossref","first-page":"1505\u2013","DOI":"10.1161\/CIRCULATIONAHA.118.034818","article-title":"Effects of sacubitril\/valsartan versus irbesartan in patients with chronic kidney disease.","volume":"138","author":"Haynes","year":"2018;","journal-title":"Circulation"},{"issue":"(11):","key":"key20250708065221_B29","doi-asserted-by":"crossref","first-page":"1077\u2013","DOI":"10.1001\/jama.2019.12843","article-title":"Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial.","volume":"322","author":"Desai","year":"2019;","journal-title":"JAMA"},{"issue":"(11):","key":"key20250708065221_B30","doi-asserted-by":"crossref","first-page":"993\u2013","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure.","volume":"371","author":"McMurray","year":"2014;","journal-title":"N Engl J Med"},{"issue":"(1):","key":"key20250708065221_B31","doi-asserted-by":"crossref","first-page":"1\u2013","DOI":"10.1536\/ihj.19-231","article-title":"The impact of sacrubitril\/valsartan on clinical treatment and hs-cTNT and NT-proBNP serum levels and the left ventricular function in patients with chronic heart failure.","volume":"61","author":"Gao","year":"2020;","journal-title":"Int Heart J"},{"issue":"(11):","key":"key20250708065221_B32","first-page":"1090.","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure.","volume":"380","year":"2019;","journal-title":"N Engl J Med"},{"issue":"(17):","key":"key20250708065221_B33","doi-asserted-by":"crossref","first-page":"1609\u2013","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction.","volume":"381","author":"Solomon","year":"2019;","journal-title":"N Engl J Med"},{"issue":"(9851):","key":"key20250708065221_B34","doi-asserted-by":"crossref","first-page":"1387\u2013","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.","volume":"380","author":"Solomon","year":"2012;","journal-title":"Lancet"},{"issue":"(11):","key":"key20250708065221_B35","doi-asserted-by":"crossref","first-page":"1354\u2013","DOI":"10.1161\/CIRCULATIONAHA.118.037077","article-title":"Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation.","volume":"139","author":"Kang","year":"2019;","journal-title":"Circulation"},{"issue":"(5):","key":"key20250708065221_B36","doi-asserted-by":"crossref","first-page":"510\u2013","DOI":"10.1002\/ejhf.232","article-title":"Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction.","volume":"17","author":"Voors","year":"2015;","journal-title":"Eur J Heart Fail"},{"issue":"(13):","key":"key20250708065221_B37","doi-asserted-by":"crossref","first-page":"1236\u2013","DOI":"10.1161\/CIRCULATIONAHA.120.047643","article-title":"Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction.","volume":"142","author":"Mc Causland","year":"2020;","journal-title":"Circulation"},{"issue":"(1):","key":"key20250708065221_B38","doi-asserted-by":"crossref","first-page":"150\u2013","DOI":"10.1111\/jch.13153","article-title":"Efficacy and safety of sacubitril\/valsartan in patients with essential hypertension uncontrolled by olmesartan: A randomized, double-blind, 8-week study.","volume":"20","author":"Cheung","year":"2018;","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"(12):","key":"key20250708065221_B39","doi-asserted-by":"crossref","first-page":"1163\u2013","DOI":"10.1093\/ajh\/hpx111","article-title":"Efficacy and safety of sacubitril\/valsartan (lcz696) compared with olmesartan in elderly Asian patients (\u226565 years) with systolic hypertension.","volume":"30","author":"Supasyndh","year":"2017;","journal-title":"Am J Hypertens"},{"issue":"(10):","key":"key20250708065221_B40","doi-asserted-by":"crossref","first-page":"1238\u2013","DOI":"10.1002\/ejhf.603","article-title":"Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis.","volume":"18","author":"Solomon","year":"2016;","journal-title":"Eur J Heart Fail"},{"issue":"(6):","key":"key20250708065221_B41","doi-asserted-by":"crossref","first-page":"489\u2013","DOI":"10.1016\/j.jchf.2018.02.004","article-title":"Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure.","volume":"6","author":"Damman","year":"2018;","journal-title":"JACC Heart Fail"},{"issue":"(10):","key":"key20250708065221_B42","doi-asserted-by":"crossref","first-page":"1380\u2013","DOI":"10.1016\/j.jchf.2023.05.014","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction according to polypharmacy status.","volume":"11","author":"Peikert","year":"2023;","journal-title":"JACC Heart Fail"},{"issue":"(7):","key":"key20250708065221_B43","doi-asserted-by":"crossref","first-page":"547\u2013","DOI":"10.1016\/S2213-8587(18)30100-1","article-title":"Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial.","volume":"6","author":"Packer","year":"2018;","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"(8):","key":"key20250708065221_B44","doi-asserted-by":"crossref","first-page":"1287\u2013","DOI":"10.1007\/s11739-019-02111-6","article-title":"Renal effects of Sacubitril\/Valsartan in heart failure with reduced ejection fraction: a real life 1-year follow-up study.","volume":"14","author":"Spannella","year":"2019;","journal-title":"Intern Emerg Med"},{"key":"key20250708065221_B45","doi-asserted-by":"crossref","first-page":"173444.","DOI":"10.1016\/j.ejphar.2020.173444","article-title":"Effects of sacubitril\/valsartan in patients with heart failure and chronic kidney disease: a meta-analysis.","volume":"884:","author":"Kang","year":"2020;","journal-title":"Eur J Pharmacol"},{"issue":"(1):","key":"key20250708065221_B46","doi-asserted-by":"crossref","first-page":"88\u2013","DOI":"10.1016\/j.mayocp.2022.06.007","article-title":"Real-world experience of angiotensin receptor-neprilysin inhibition in reduced ejection fraction heart failure patients with advanced kidney disease.","volume":"98","author":"Chang","year":"2023;","journal-title":"Mayo Clin Proc"},{"key":"key20250708065221_B47","unstructured":"Boehringer Ingelheim. Boehringer Ingelheim India. 2022 [cited 2023 14th September]. Boehringer Ingelheim\u2019s Jardiance\u00ae (empagliflozin) approved by CDSCO as the first treatment for heart failure with preserved ejection fraction (HFpEF) in India. Available from: https:\/\/boehringer-ingelheim.com\/in\/media-overview\/press-releases\/boehringer-ingelheims-jardiancer-empagliflozin-approved-cdsco-first"},{"key":"key20250708065221_B48","unstructured":"Astra Zeneca. Astra Zeneca\u2019s dapagliflozin gets additional indication approval for treatment of Heart Failure in adults in India. 2023. Available from: https:\/\/www.astrazeneca.in\/media\/press-releases\/2023\/astrazenecas-dapagliflozin-gets-additional-indication-approval-for-treatment-of-heart-failure-in-adults-in-india.html"},{"key":"key20250708065221_B49","unstructured":"Central Drugs Standards Control Organisation. Approval of dapagliflozin 5 mg\/10 mg. List of approved drugs from 01-01-2015 to 31-01-2015. Central Drugs Standards Control Organisation; 2015. Available from: https:\/\/cspc.in\/dic\/pdf\/Approved%20drugs%20In%20India%20Year%202015.pdf"},{"key":"key20250708065221_B50","unstructured":"Central Drugs Standards Control Organisation. Approval of empagliflozin 10 mg\/25 mg. List of approved drugs from 01-01-2015 to 31-01-2015. Central Drugs Standards Control Organisation; 2015. Available from: https:\/\/cdscoonline.gov.in\/CDSCO\/Drugs"},{"key":"key20250708065221_B51","unstructured":"Central Drugs Standards Control Organisation. Approval of canagliflozin. Drugs approved from 1st January 2014 to 31st December 2014. Central Drugs Standards Control Organisation; 2014. Available from: https:\/\/cdsco.gov.in\/opencms\/opencms\/system\/modules\/CDSCO.WEB\/elements\/download_file_division.jsp?num_id=MzIyOA=="},{"key":"key20250708065221_B52","unstructured":"Central Drugs Standards Control Organisation. Approval of dapagliflozin 5 mg\/10 mg. Recommendations of the SEC (Cardiovascular & Renal) made in its 126th meeting held on 24.05.2023 at CDSCO HQ, New Delhi. Central Drugs Standards Control Organisation; 2023. Available from: https:\/\/cdsco.gov.in\/opencms\/resources\/UploadCDSCOWeb\/2018\/UploadCommitteeFiles\/Recommendations%20Cardiovascular%20&%20Renal%20Dated%2024.05.2023.pdf"},{"key":"key20250708065221_B53","unstructured":"Central Drugs Standards Control Organisation. Approval of empagliflozin 10 mg\/25 mg. Recommendations of the SEC (Cardiovascular & Renal) made in its 99th meeting held on 17.03.2021 at CDSCO (HQ), New Delhi. Central Drugs Standards Control Organisation; 2021. Available from: https:\/\/cdsco.gov.in\/opencms\/resources\/UploadCDSCOWeb\/2018\/UploadCommitteeFiles\/Recommendations%20Cardio%2017.3.22.pdf"},{"issue":"(24):","key":"key20250708065221_B54","doi-asserted-by":"crossref","first-page":"2295\u2013","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.","volume":"380","author":"Perkovic","year":"2019;","journal-title":"N Engl J Med"},{"key":"key20250708065221_B55","doi-asserted-by":"crossref","first-page":"141\u2013","DOI":"10.1016\/j.ahj.2020.12.008","article-title":"Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: results from the CREDENCE trial.","volume":"233:","author":"Sarraju","year":"2021;","journal-title":"Am Heart J"},{"issue":"(15):","key":"key20250708065221_B56","doi-asserted-by":"crossref","first-page":"1436\u2013","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease.","volume":"383","author":"Heerspink","year":"2020;","journal-title":"N Engl J Med"},{"issue":"(11):","key":"key20250708065221_B57","doi-asserted-by":"crossref","first-page":"807\u2013","DOI":"10.1016\/j.jchf.2021.06.017","article-title":"Effects of dapagliflozin in patients with kidney disease, with and without heart failure.","volume":"9","author":"McMurray","year":"2021;","journal-title":"JACC Heart Fail"},{"issue":"(2):","key":"key20250708065221_B58","first-page":"117\u2013","article-title":"Empagliflozin in patients with chronic kidney disease.","volume":"388","author":"Herrington","year":"2023;","journal-title":"N Engl J Med"},{"issue":"(7):","key":"key20250708065221_B59","doi-asserted-by":"crossref","first-page":"e020053.","DOI":"10.1161\/JAHA.120.020053","article-title":"Cardio\/kidney composite end points: a post hoc analysis of the EMPA-REG OUTCOME trial.","volume":"10","author":"Ferreira","year":"2021;","journal-title":"J Am Heart Assoc"},{"issue":"(4):","key":"key20250708065221_B60","doi-asserted-by":"crossref","first-page":"298\u2013","DOI":"10.1161\/CIRCULATIONAHA.120.050391","article-title":"Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF.","volume":"143","author":"Jhund","year":"2021;","journal-title":"Circulation"},{"issue":"(4):","key":"key20250708065221_B61","doi-asserted-by":"crossref","first-page":"310\u2013","DOI":"10.1161\/CIRCULATIONAHA.120.051685","article-title":"Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from EMPEROR-Reduced.","volume":"143","author":"Zannad","year":"2021;","journal-title":"Circulation"},{"issue":"(16):","key":"key20250708065221_B62","doi-asserted-by":"crossref","first-page":"1451\u2013","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction.","volume":"385","author":"Anker","year":"2021;","journal-title":"N Engl J Med"},{"issue":"(7):","key":"key20250708065221_B63","doi-asserted-by":"crossref","first-page":"1463\u2013","DOI":"10.1016\/j.ekir.2022.04.094","article-title":"Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations.","volume":"7","author":"Yau","year":"2022;","journal-title":"Kidney Int Rep"},{"issue":"(1):","key":"key20250708065221_B64","doi-asserted-by":"crossref","first-page":"27\u2013","DOI":"10.1016\/S2213-8587(19)30384-5","article-title":"Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.","volume":"8","author":"Heerspink","year":"2020;","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"(11):","key":"key20250708065221_B65","doi-asserted-by":"crossref","first-page":"1152\u2013","DOI":"10.1016\/j.jacc.2011.04.041","article-title":"Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis.","volume":"58","author":"Badve","year":"2011;","journal-title":"J Am Coll Cardiol"},{"issue":"(6):","key":"key20250708065221_B66","doi-asserted-by":"crossref","first-page":"607\u2013","DOI":"10.1093\/eurjhf\/hfq038","article-title":"Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial.","volume":"12","author":"Castagno","year":"2010;","journal-title":"Eur J Heart Fail"},{"issue":"(23):","key":"key20250708065221_B67","doi-asserted-by":"crossref","first-page":"2893\u2013","DOI":"10.1016\/j.jacc.2019.09.059","article-title":"Impact of renal impairment on beta-blocker efficacy in patients with heart failure.","volume":"74","author":"Kotecha","year":"2019;","journal-title":"J Am Coll Cardiol"},{"issue":"(4):","key":"key20250708065221_B68","first-page":"1765\u2013","article-title":"A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees.","volume":"90","year":"1994;","journal-title":"Circulation"},{"issue":"(9146):","key":"key20250708065221_B69","first-page":"9\u2013","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial.","volume":"353","author":"CIBIS-II Investigators and Committee.","year":"1999;","journal-title":"Lancet"},{"issue":"(11):","key":"key20250708065221_B70","doi-asserted-by":"crossref","first-page":"e007180.","DOI":"10.1161\/CIRCHEARTFAILURE.120.007180","article-title":"Association between \u03b2-blocker use and mortality\/morbidity in patients with heart failure with reduced, midrange, and preserved ejection fraction and advanced chronic kidney disease.","volume":"13","author":"Fu","year":"2020;","journal-title":"Circ Heart Fail"},{"issue":"(3):","key":"key20250708065221_B71","doi-asserted-by":"crossref","first-page":"731\u2013","DOI":"10.1093\/ckj\/sfaa249","article-title":"\u03b2-blockers in hemodialysis: simple questions, complicated answers.","volume":"14","author":"Hundemer","year":"2021;","journal-title":"Clin Kidney J"},{"issue":"(3):","key":"key20250708065221_B72","doi-asserted-by":"crossref","first-page":"983\u2013","DOI":"10.1093\/ckj\/sfaa248","article-title":"Comparative effectiveness of bisoprolol and carvedilol among patients receiving maintenance hemodialysis.","volume":"14","author":"Wu","year":"2021;","journal-title":"Clin Kidney J"},{"issue":"(3):","key":"key20250708065221_B73","doi-asserted-by":"crossref","first-page":"445\u2013","DOI":"10.1007\/s40119-023-00323-8","article-title":"Practical recommendations for the use of angiotensin receptor-neprilysin inhibitors (ARNI) in heart failure: insights from Indian cardiologists.","volume":"12","author":"Dalal","year":"2023;","journal-title":"Cardiol Ther"},{"issue":"(1):","key":"key20250708065221_B74","doi-asserted-by":"crossref","first-page":"310.","DOI":"10.1186\/s12882-023-03339-3","article-title":"UK Kidney Association clinical practice guideline: sodium-glucose co-transporter-2 (SGLT-2) inhibition in adults with kidney disease 2023 update.","volume":"24","author":"Roddick","year":"2023;","journal-title":"BMC Nephrol"},{"issue":"(3):","key":"key20250708065221_B75","doi-asserted-by":"crossref","first-page":"381\u2013","DOI":"10.7326\/M22-2904","article-title":"Diabetes management in chronic kidney disease: synopsis of the KDIGO 2022 clinical practice guideline update.","volume":"176","author":"Navaneethan","year":"2023;","journal-title":"Ann Intern Med"},{"issue":"(Suppl 1):","key":"key20250708065221_B76","doi-asserted-by":"crossref","first-page":"S191\u2013","DOI":"10.2337\/dc23-S011","article-title":"11. Chronic kidney disease and risk management: standards of care in diabetes-2023.","volume":"46","author":"ElSayed","year":"2023;","journal-title":"Diabetes Care"},{"issue":"(Suppl 1):","key":"key20250708065221_B77","doi-asserted-by":"crossref","first-page":"S158\u2013","DOI":"10.2337\/dc23-S010","article-title":"10. Cardiovascular disease and risk management: standards of care in diabetes-2023.","volume":"46","author":"ElSayed","year":"2023;","journal-title":"Diabetes Care"},{"issue":"(1):","key":"key20250708065221_B78","doi-asserted-by":"crossref","first-page":"5\u2013","DOI":"10.1002\/ejhf.3024","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC.","volume":"26","author":"Authors\/Task Force Members,","year":"2024;","journal-title":"Eur J Heart Fail"},{"issue":"(18):","key":"key20250708065221_B79","first-page":"e895\u2013","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines.","volume":"145","author":"Heidenreich","year":"2022;","journal-title":"Circulation"},{"issue":"(3):","key":"key20250708065221_B80","doi-asserted-by":"crossref","first-page":"133\u2013","DOI":"10.4103\/jpcs.jpcs_1_18","article-title":"Heart failure guidelines for India: update 2017.","volume":"3","author":"Seth","year":"2017;","journal-title":"J Pract Cardiovasc Sci"},{"issue":"(3):","key":"key20250708065221_B81","doi-asserted-by":"crossref","first-page":"160\u2013","DOI":"10.1016\/j.tcm.2019.05.003","article-title":"Blood pressure and the new ACC\/AHA hypertension guidelines.","volume":"30","author":"Flack","year":"2020;","journal-title":"Trends Cardiovasc Med"},{"issue":"(12):","key":"key20250708065221_B82","doi-asserted-by":"crossref","first-page":"1874\u2013","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA).","volume":"41","author":"Mancia","year":"2023;","journal-title":"J Hypertens"},{"issue":"(6):","key":"key20250708065221_B83","doi-asserted-by":"crossref","first-page":"1334\u2013","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"2020 International Society of Hypertension global hypertension practice guidelines.","volume":"75","author":"Unger","year":"2020;","journal-title":"Hypertension"},{"key":"key20250708065221_B84","unstructured":"Ministry of Health and Family Welfare, Government of India. Medical Officers\u2019 Manual for Prevention and Management of Chronic Kidney Diseases under the \u201cNational Programme for Prevention and Control of Noncommunicable Diseases. Ministry of Health and Family Welfare, Government of India; 2022. Available from: https:\/\/dghs.gov.in\/WriteReadData\/userfiles\/file\/NPCDCS\/Fin%20-%20CKD%20guidelines.pdf"},{"issue":"(11):","key":"key20250708065221_B85","doi-asserted-by":"crossref","first-page":"1154\u2013","DOI":"10.1503\/cmaj.080351","article-title":"Guidelines for the management of chronic kidney disease.","volume":"179","author":"Levin","year":"2008;","journal-title":"CMAJ"},{"issue":"(11):","key":"key20250708065221_B86","doi-asserted-by":"crossref","first-page":"1157\u2013","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular disease in chronic kidney disease.","volume":"143","author":"Jankowski","year":"2021;","journal-title":"Circulation"},{"issue":"(8):","key":"key20250708065221_B87","doi-asserted-by":"crossref","first-page":"1805\u2013","DOI":"10.2337\/dc21-0076","article-title":"The effect of dapagliflozin on albuminuria in DECLARE-TIMI 58.","volume":"44","author":"Mosenzon","year":"2021;","journal-title":"Diabetes Care"}],"container-title":["Journal of the Association of Physicians of India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T02:52:43Z","timestamp":1751943163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.japi.org\/article\/japi-72-5-77"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":87,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.59556\/japi.72.0543"],"URL":"https:\/\/doi.org\/10.59556\/japi.72.0543","relation":{},"ISSN":["0004-5772"],"issn-type":[{"value":"0004-5772","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]}}}